Reference SummaryPond AC, Cancer Res 2010 Jun 15;70(12):4868-79
Title |
Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer. | ||||||||
Authors |
Pond AC; Herschkowitz JI; Schwertfeger KL; Welm B; Zhang Y; York B; Cardiff RD; Hilsenbeck S; Perou CM; Creighton CJ; Lloyd RE; Rosen JM | ||||||||
Journal |
Cancer Res | ||||||||
Volume |
70 | ||||||||
Issue |
12 | ||||||||
Year |
2010 | ||||||||
Pages |
4868-79 | ||||||||
Abstract |
Fibroblast growth factor (FGF) cooperates with the Wnt/beta-catenin pathway to promote mammary tumorigenesis. To investigate the mechanisms involved in FGF/Wnt cooperation, we genetically engineered a model of inducible FGF receptor (iFGFR) signaling in the context of the well-established mouse mammary tumor virus-Wnt-1 transgenic mouse. In the bigenic mice, iFGFR1 activation dramatically enhanced mammary tumorigenesis. Expression microarray analysis did not show transcriptional enhancement of Wnt/beta-catenin target genes but instead showed a translational gene signature that also correlated with elevated FGFR1 and FGFR2 in human breast cancer data sets. Additionally, iFGFR1 activation enhanced recruitment of RNA to polysomes, resulting in a marked increase in protein expression of several different Wnt/beta-catenin target genes. FGF pathway activation stimulated extracellular signal-regulated kinase and the phosphorylation of key translation regulators both in vivo in the mouse model and in vitro in a human breast cancer cell line. Our results suggest that cooperation of the FGF and Wnt pathways in mammary tumorigenesis is based on the activation of protein translational pathways that result in, but are not limited to, increased expression of Wnt/beta-catenin target genes (at the level of protein translation). Further, they reveal protein translation initiation factors as potential therapeutic targets for human breast cancers with alterations in FGF signaling. | ||||||||
Links |
J:160915 – MGI References 20501844 – National Library of Medicine/PubMed |
||||||||
Strain Notes
|
|||||||||
| Strain | Model Name | Treatment Agent(s) | Organ Affected | Frequency | Model Details |
|---|---|---|---|---|---|
| FVB-Tg(Wnt1)1Hev | Mammary gland hyperplasia | Mammary gland |
observed |
||
| FVB-Tg(MMTV-Fgfr1)4775Jmr Tg(Wnt1)1Hev | Mammary gland hyperplasia | Mammary gland |
observed |
||
| FVB-Tg(MMTV-Fgfr1)4775Jmr Tg(Wnt1)1Hev | Mammary gland lesion - nodular |
|
Mammary gland |
observed |
|
| FVB-Tg(MMTV-Fgfr2)#Jmr Tg(Wnt1)1Hev | Mammary gland tumor | Mammary gland |
observed |
||
| FVB-Tg(MMTV-Fgfr1)4775Jmr Tg(Wnt1)1Hev | Mammary gland tumor - solid |
|
Mammary gland |
100 |
|
| FVB-Tg(Wnt1)1Hev | Mammary gland tumor - type P |
|
Mammary gland |
52 |